Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nine cases of primary malignant melanoma of the penis and male urethra are presented. The age range of the patients was 57-77 years. Five patients had intermittent bleeding, one had pain, and three were asymptomatic. Six patients had the melanoma on the glans or prepuce and three in the urethra; two presented with inguinal lymph node metastases. Penile amputation was performed in six patients, local excision in three, groin dissection in four, and one was given radiotherapy. Postoperative metastases were seen in eight patients, four of whom were treated with surgery, alone or in combination with radiotherapy, and one with chemotherapy. Two patients are still living, at 2 and 14 years after diagnosis, respectively. Seven patients have died of their tumors, five of them within 2 years. This confirms the consensus of available reports that, irrespective of what type of therapy is used, prognosis is poor in patients with malignant melanoma of the penis and urethra.
 ...
PMID:Malignant melanoma of the penis and male urethra. Report of nine cases and review of the literature. 379 Nov 67

Ten dogs with carcinoma of the prostate gland were treated with intraoperative orthovoltage radiotherapy (radiation therapy to surgically exposed tumors). Seven dogs had tumor growth confined to the prostate gland and urethra, and 3 dogs had carcinoma of the prostate gland and regional lymph node involvement. Total radiation doses delivered to the prostate gland of 9 dogs and the affected regional lymph nodes of 3 dogs, using orthovoltage x-rays, ranged from 20 to 30 Gy. Carcinoma of the prostate gland of one dog was intraoperatively irradiated to 15 Gy and was then given a boost of 40 Gy, using cobalt-60 teletherapy. Survival time ranged from 41 to 750 days after intraoperative radiotherapy. Median and mean survival times for all dogs were 114 and 196 days, respectively. The median survival time for 7 dogs with localized prostatic carcinoma was 180 days, which was longer, but not significantly longer (P = 0.09), than the median survival time of 80 days in 3 dogs having prostatic carcinoma and metastatic disease. Intraoperative radiotherapy was tolerated well and caused complete response in 5 dogs. However, surgical complications in 2 dogs, which had subtotal lymphadenectomy or prostatic biopsy performed concurrently at the time of irradiation, resulted ultimately in their deaths. The 2 other dogs with metastatic disease and 1 dog without metastatic disease also had poor response to treatment. Our results indicated that intraoperative radiotherapy is an effective treatment for localized prostatic carcinoma in the dog.
 ...
PMID:Intraoperative radiotherapy of carcinoma of the prostate gland in ten dogs. 381 16

Recent enthusiasm for the use of intensive regimens of intravesical chemotherapy in the management of various forms of superficial transitional cell carcinoma of the bladder prompted us to examine retrospectively a group of patients with carcinoma in situ treated by such regimens who failed with progressive and metastatic cancer. Of 8 patients with flat carcinoma in situ treated with thiotepa 5 presented initially with concomitant solitary stage T1 papillary tumors that were resected successfully at initial presentation. Six patients had diffuse or multifocal carcinoma in situ, while 2 others had only a solitary focus of in situ disease. All patients had persistently positive urinary cytology studies during treatment, prompting 3 of them to receive intravesical mitomycin C following their course of thiotepa. Involvement of the prostatic urethra developed during therapy in 3 patients and 3 had muscle-infiltrative disease. At cystectomy 3 of 7 patients had positive pelvic lymph nodes and 4 died of distant metastases at an average of 8 months after cystectomy. These results suggest that despite the apparent advances that have been made in the control of recurrent superficial transitional cell bladder cancer, the intrinsic behavior of some forms of the disease may determine cancer progression. Identification of such patients is indicated for the institution of early aggressive treatment, which in the end may actually be the more conservative therapeutic approach.
 ...
PMID:Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? 393 86

Thirteen cases of prostatic adenocarcinoma with endometrioid features were reviewed. The patients were older men (49-81 years) presenting with symptoms of hematuria and urinary obstruction. Each of the tumors displayed exophytic growth into the prostatic urethra, with involvement of the verumontanum. The urethral orifices of the large (primary) prostatic ducts were uniformly involved, and coexistent invasive (acinar) adenocarcinoma was identified in 10 cases (77%). The tumors exhibited a complex glandular pattern strikingly similar to uterine endometrial carcinoma, with prominent papillary formation in six cases. All cases demonstrated intense cytoplasmic immunoreactivity for prostatic acid phosphatase and prostate-specific antigen in at least part of the tumor. Focal staining for carcinoembryonic antigen was seen in three cases. Five tumors examined ultrastructurally demonstrated typical features of prostatic adenocarcinoma. Follow-up information was available on all 13 patients (6-83 months). Seven patients died of metastatic tumor (9-70 months after diagnosis), and the other six patients exhibited recurrent local or metastatic tumor. The sites of metastases were identical to those seen with invasive "acinar" prostatic adenocarcinoma, including pelvic lymph nodes, bones, and lungs. Crude 5-year survival was 15%, with a mean survival of 37 months. Adjuvant therapy provided palliative relief for many patients, but did not appear to influence survival. These findings indicate that endometrioid carcinoma is a histologically distinct variant of prostatic adenocarcinoma, with a more aggressive clinical behavior than previously thought.
 ...
PMID:Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. 409 Nov 89

Most radiologists accept that modest doses of irradiation (4500-5000 rad/4 1/2-5 weeks) can control subclinical regional lymph node metastases from squamous cell carcinomas of the head and neck and adenocarcinomas of the breast. There have been few reports concerning elective irradiation of the ilioinguinal region. Between October 1964 and March 1980, 91 patients whose primary cancers placed the ilioinguinal lymph nodes at risk received elective irradiation at the University of Florida. Included are patients with cancers of the vulva, penis, urethra, anus and lower anal canal, and cervix or vaginal cancers that involved the distal one-third of the vagina. In 81 patients, both inguinal areas were clinically negative; in 10 patients, one inguinal area was positive and the other negative by clinical examination. Tumor doses most commonly used were 4500-5000 rad/5 weeks (180 rad to 200 rad per fraction). With a minimum two-year follow-up, there were only two regional failures in patients whose primaries were controlled; both failures occurred outside of the radiation fields. The single significant complication was a bilateral femoral neck fracture. The inguinal areas of four patients developed mild to moderate fibrosis. One patient with moderate fibrosis had bilateral mild leg edema that was questionably related to irradiation. No other instances of leg or genital edema were noted. Complications were dose-related. The advantages and disadvantages of elective ilioinguinal node irradiation versus elective inguinal lymph node dissection or no elective treatment are discussed.
 ...
PMID:Elective ilioinguinal lymph node irradiation. 642 97

Eleven cases of histologically proven transitional cell carcinoma of the bladder or urethra of the dog were selected for evaluation and characterization of the varied radiographic appearances of the lungs. In the 8 dogs with metastases, those appearances included radiographically normal pulmonary parenchyma, a semidense, diffuse, lacelike haze referred to as interstitial opacity, nodular interstitial opacity, and consolidations. One affected dog had hilar lymphadenopathy. In the 3 dogs without pulmonary metastases, the radiographic appearance was either normal pulmonary parenchyma or increased unstructured interstitial opacity. Of all dogs in the study, 6 had a radiographic appearance of increased unstructured interstitial opacity. Four of those 6 had histologically proven metastases in the peribronchiolar lymphatics or alveolar capillaries. Dyspnea was not identified in any of the affected dogs. The radiographic appearance for 3 of the 8 dogs with pulmonary metastases was misinterpreted as opacity compatible with age. The radiographic appearance for 1 of the 3 dogs without pulmonary metastases was misinterpreted as highly suspect for metastases.
 ...
PMID:Radiographic appearance of pulmonary metastases from transitional cell carcinoma of the bladder and urethra of the dog. 646 38

During a 10-year period 174 consecutive male patients underwent radical cystectomy with pelvic lymph node dissection for transitional cell cancer of the bladder. Urethrectomy, either performed en bloc with the cystectomy or secondarily, was required in 23 patients. Of these 23 patients 9 died of metastatic disease and 4 deaths were believed to be directly related to development of tumor in the urethra. A careful review of our data suggests that patient selection is possible so that urethrectomy in all patients undergoing cystectomy may be avoided, while maintaining the ability to treat those at risk for carcinoma in the retained urethra before invasion occurs. We recommend the following indications for urethrectomy: 1) en bloc cystourethrectomy for clinically overt involvement of the anterior urethra with carcinoma or tumor extending into the prostatic urethra, 2) immediate or delayed total urethrectomy either during the initial hospitalization or within 2 months of cystectomy for all patients with pathological evidence of invasion of the prostate (P4) or carcinoma in situ of the prostatic urethra, 3) indefinite close followup of all patients whose bladder specimens demonstrate carcinoma in situ (urethral cytology within 4 months of cystectomy and every year thereafter, and immediate total urethrectomy for any urethral cytology positive for malignant cells), and 4) immediate total urethrectomy for any patient experiencing bloody urethral discharge.
 ...
PMID:Indications for urethrectomy in men undergoing single stage radical cystectomy for bladder cancer. 670 78

Of 15 women with primary urethral carcinoma 2 had tumors confined to the urethra and were managed successfully by an operation. Of the 9 patients with tumor extending to the surrounding structures 6 (67 per cent) died of complications related to inadequate control of the primary tumor. The last 4 patients had stage D1 disease or greater at initial diagnosis and died of distant metastases. Our current approach for patients with locally advanced disease is combined brachytherapy and operation in an effort to eradicate the primary tumor, since morbidity and mortality result from failure to control the local tumor.
 ...
PMID:Carcinoma of the female urethra: reassessment of modes of therapy. 685 68

We report a case of amelanotic malignant melanoma of the female urethra. The clinical course was unusually long and complicated by asynchronous resectable metastases to the lung and the brain. The patient died of generalized metastasis in spite of successful resection of the metastatic lesions and post-operative chemotherapy, two years and five months after the first presentation. To the best of our knowledge this is the second reported case of amelanotic melanoma in the female urethra.
 ...
PMID:A case of amelanotic malignant melanoma of the female urethra. 688 60

The authors undertake a complete review of the literature concerning the various methods of spread of bladder tumours. They successively consider spread through the thickness of the bladder wall, surface extension, direct implantation of exfoliated cells, lymphatic spread, and venous dissemination both in the bladder wall as well as to the viscera by metastases. It is difficult to give a brief analysis of such an exhaustive review. However, a number of facts are worthy of emphasis: --the frequency of invasion of the seminal vesicles and the prostate; --the reliability of combined clinical, radiological and endoscopic findings, which may be used to differentiate deep tumours and superficial tumours in more than 80% of cases; --the importance of methods which await development, such as the scanner and, above all, ultrasound techniques; --the importance of study of the vesical mucosa at a distance from the tumour itself, both by fluorescent cystoscopic methods, as well as by distant biopsies (30 to 50% of premalignant cell changes found in cystoscopically normal zones); --the frequency if invasion of the terminal portions of the ureters (10% on average) and of the urethra (12 to 15%); --the prognostic gravity of tumour emboli in the intraparietal lymph vessels, the presence of which reduces the chances of cure at 5 years by two thirds; --the usual limitation of the first lymph node spread to the external iliac and hypogastric vessels with the exception of tumours of the bladder neck, where the first lymph node spread occurs to the aortic bifurcation; --the gravity of the presence of emboli in the parietal veins which reduces chances of survival at 5 years by half; --finally, the recently recognized frequency of secondary bone tumours; --and the supposed frequency of infraclinical metastases which would be a considerable argument in favour of complementary chemotherapy in therapeutic protocol for carcinomas of the bladder.
 ...
PMID:[Various methods of spread of bladder tumours (author's transl)]. 703 79


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>